Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells

Menopause

Volumn 15, Issue 3, 2008, Pages 570-574

  Carroll, Candace E ^a   Ellersieck, Mark R ^a   Hyder, Salman M ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Breast cancer; Curcumin; Progestins; VEGF

Indexed keywords

CURCUMIN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PROTEIN SECRETION;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CURCUMIN; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS, HORMONE-DEPENDENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43249100098     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31814fae5d     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Writing Group for the Women's Heath Initiative Investigators. Risks and benefits of estrogens plus progestins in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
4. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
5. Moore M, Spence J, Kiningham K, Dillon J. Progestin inhibition of cell death in human breast cancer cells lines. J Steroid Biochem Mol Biol 2006;98:218-227.
6. Aupperlee M, Kariangina A, Osuch J, Haslam SZ. Progestins and breast cancer. Breast Dis 2005-2006;24:37-57.
7. Hyder SM. Sex steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat Cancer 2006;13:667-687.
8. Benakanakere I, Williford CB, Schnell J, et al. Natural and synthetic progestins accelerate 7,12-dimethylbenza anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 2006;12:4062-4071.
9. Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001;92:469-473.
10. Liang Y, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced VEGF from human breast cancer cells: paracrine and autocrine effects. Endocrinology 2005;146:3632-3641.
11. Howtitz KB. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 1992;12:146-163.
12. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-2087.
13. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 1998;217:369-378.
14. Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ Health Prospect 1998;106:807-812.
15. Campbell FC, Collett GP. Chemopreventive properties of curcumin. Future Oncol 2006;1:405-414.
16. Singletary K, MacDonald C, Wallig M, Fisher C. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett 1996;103:137-141.
17. Shao Z, Shen Z, Liu C, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 2002;98:234-240.
18. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Statist 1981;35:124-129.
19. Chew V. Comparison Among Treatment Means and Analysis of Variance. Washington, DC: Agricultural Research Service, USDA; October 1977: (ARS/H/6 Report) 32-35.
20. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 1999;154:11-20.
21. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factors induce proliferation of breast cancer cells and inhibit the antiproliferative activity of anti-hormones. Endocr Relat Cancer 2006;13:905-919.
22. Wu J, Brandt S, Hyder SM. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. Mol Endocrinol 2005;19:312-326.
23. Carnevale RP, Proietti CJ, Salatino M, et al. Progestin effects on breast cancer cell proliferation, protease activation, and in vivo development of metastatic phenotype all depend on PR capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 2007;21:1335-1358.
24. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci U S A 2003;100:2231-2236.
25. Karteris E, Zervou S, Pang Y, et al. Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 2006;20:1519-1534.
26. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-6854.